Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23Andme Holding Co. (NQ: ME )

0.3835 -0.0048 (-1.24%)
Streaming Delayed Price Updated: 12:40 PM EDT, Oct 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about 23Andme Holding Co.

< Previous 1 2 3 Next >
23andMe Reports FY2023 Third Quarter Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
23andMe to Report FY2023 Third Quarter Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season
From 23andMe Holding Co.
Via GlobeNewswire
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes. 
Via TheNewswire.com
23andMe Reports FY2023 Second Quarter Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
The presentation outlines plans for the expansion phase of the study (part B), including the specific tumor indications where 23ME-00610 will be tested for anticancer activity 
From 23andMe Holding Co.
Via GlobeNewswire
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication
FDA 510(k) clearance allows 23andMe to report genetics associated with processing of certain statins, provides interpretive drug information for simvastatin, and removes the requirement for... 
From 23andMe Holding Co.
Via GlobeNewswire
23andMe to Report FY2023 Second Quarter Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
23andMe to Present at Upcoming Investor Conferences
From 23andMe Holding Co.
Via GlobeNewswire
23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
Poster to provide details on study design and expansion phase for ongoing Phase 1 study in patients with advanced solid malignancies 
From 23andMe Holding Co.
Via GlobeNewswire
23andMe to Report FY2023 First Quarter Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
Florida Credit Firm Leading Credit Repair Firm in all 50 states.
5 reasons why we are Rated #1 Credit Repair Firm in the United States. Helping Clients all over the 50 states fixing their credit. 
Via IssueWire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.